| The Multi-Center Study of Shear Wave Elastography on Thyroid Nodules (NCT02937467) | Peking University Cancer Hospital & Institute | 2016-12-01 |
| Epidiolex and Drug Resistant Epilepsy in Children (NCT02397863) | Augusta University | 2014-12-01 |
| Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation (NCT02149732) | Seoul National University Hospital | 2014-05-01 |
| Therapeutic Efficacy of "Abroma Agusta" in HbA1c % in NIDDM (NCT02065674) | Fr Muller Homoeopathic Medical College | 2014-02-01 |
| Weight-bearing Measuring Device to Determine Normative Percentage Body-Weight/Weight-Bearing Values and Weight-bearing Gait Characteristics (NCT01112332) | Meir Medical Center | 2010-03-01 |
| Managed Access Programs for CTL019, Tisagenlecleucel (NCT03601442) | Novartis Pharmaceuticals | |
| Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants (NCT01881334) | Joanne Kurtzberg, MD | |
| Managed Access Programs for ABL001, Asciminib (NCT04360005) | Novartis Pharmaceuticals | |
| Managed Access Programs for SEG101, Crizanlizumab (NCT03720626) | Novartis Pharmaceuticals | |
| Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease (NCT05047328) | ElsaLys Biotech | |
| A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma (NCT03015844) | Northwell Health | |
| Expanded Access to Ziftomenib (NCT05738538) | Kura Oncology, Inc. | |
| Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping (NCT07250737) | Avidity Biosciences, Inc. | |
| Expanded Access for Iberdomide (NCT07434960) | Bristol-Myers Squibb | |
| The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder (NCT00854841) | Pusan National University Hospital | |
| An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC) (NCT06910137) | Incyte Corporation | |
| (Bispecific) Antibodies in Cancer Patients (NCT05119257) | University Hospital Tuebingen | |
| Effect of Low Level Laser Therapy on Endometrial Cells: An In Vitro Study (NCT02764034) | Cairo University | |
| Effect of Genes on Rosuvastatin Therapy for Hyperlipidemia (NCT00934258) | National Taiwan University Hospital | |
| Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma (NCT07573215) | Revolution Medicines, Inc. | |
| A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies (NCT04008524) | Institute of Hematology & Blood Diseases Hospital, China | |
| Expanded Access Program for OOS Obe-cel (NCT06799221) | Autolus Limited | |
| Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer (NCT07535359) | Daiichi Sankyo | |
| Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) (NCT04233047) | ViiV Healthcare | |
| Study on Pressure Values Measured on Three Alternative Sites of the Lower Limbs Compared to the Arm (NCT02529735) | Centre Hospitalier Sud Francilien | |
| Lamprene Multiple Patient Program (NCT04334070) | Novartis Pharmaceuticals | |
| Phone Intervention for Alcohol (ETOH) Use in Emergency Department Motor Vehicle Crash (ED MVC) Patients (NCT00457548) | Rhode Island Hospital | |
| An EAP Treatment Protocol of Zipalertinib (NCT07601399) | Taiho Oncology, Inc. | |
| IFx-Hu2.0 Expanded Access Program (NCT04853602) | TuHURA Biosciences, Inc. | |
| A Compassionate Use (CU) Program of Odronextamab (NCT05619367) | Regeneron Pharmaceuticals | |
| Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis (NCT07689942) | Biodexa Pharmaceuticals | |
| Cartilage Tissue Engineering (NCT01301664) | Chin-Hung Chang | |
| A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema (NCT01487044) | Retina Institute of Hawaii | |
| Karyopharm Expanded Access Program for Selinexor (NCT07215832) | Karyopharm Therapeutics Inc | |
| 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol (NCT01163383) | John Maris | |
| Expanded Access to CD34+ Selection Utilizing Miltenyi CliniMACS Prodigy® for Patients Receiving Peripheral Blood Stem Cell Transplantations and Stem Cell Boosts (NCT06731036) | University of Florida | |
| An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303 (NCT03778424) | Eisai Inc. | |
| Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis (NCT04474990) | Vanda Pharmaceuticals | |
| Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections (NCT06433128) | Basilea Pharmaceutica | |
| Individual Patient Compassionate Use of Nirogacestat (NCT05041036) | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | |
| Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD) (NCT06173024) | Takeda | |
| Compassionate Use of Ubamatamab (NCT07502716) | Regeneron Pharmaceuticals | |
| An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric Hypoglycemia (NCT07582874) | Amylyx Pharmaceuticals Inc. | |
| Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children (NCT05424731) | DBV Technologies | |
| Expanded Access for Apixaban (NCT05187286) | Bristol-Myers Squibb | |
| Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS (NCT06796426) | Arrowhead Pharmaceuticals | |
| Expanded Access to Tavapadon (NCT07158827) | AbbVie | |
| Bacteriophage Clinical Trial for Periprosthetic Joint Infection of Multidrug Resistant Pseudomonas Aeruginosa (NCT06798168) | Ottawa Hospital Research Institute | |
| Expanded Access/Compassionate Use of Rugonersen in Patients With Angelman Syndrome (NCT07136454) | Oak Hill Bio Ltd | |
| ITM11 Expanded Access Program (NCT07497984) | ITM Solucin GmbH | |
| Tension-Type Headache Gene Expression and Methylation (NCT06562855) | University of Gaziantep | |
| Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease (NCT01476163) | Amicus Therapeutics | |
| Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat (NCT07216378) | KalVista Pharmaceuticals, Ltd. | |
| Expanded Use in Persistent (B. Microti) Babesiosis (NCT06478641) | 60 Degrees Pharmaceuticals LLC | |
| Expanded Access for Repotrectinib (NCT05926232) | Bristol-Myers Squibb | |
| Mechanism of Effectiveness of Neurosurgery Treatments for Durable Pain (NCT03412539) | Tel-Aviv Sourasky Medical Center | |
| NuvOx Expanded Access (NCT07748299) | NuvOx LLC | |
| Managed Access Program of Venglustat in Pediatric and Adult Patients With Type 3 Gaucher Disease (GD3). (NCT07675031) | Sanofi | |
| MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer (NCT06980519) | Monopar Therapeutics | |
| Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy (NCT01250808) | Peking University | |
| Expanded Access of Occlutech's Atrial Flow Regulator (NCT07421557) | Occlutech International AB | |
| Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B) (NCT07733856) | Spruce Biosciences | |
| An Intermediate Size Expanded Access Protocol of Elamipretide (NCT04689360) | Stealth BioTherapeutics Inc. | |
| Managed Access Programs for INC424, Ruxolitinib (NCT04745637) | Novartis Pharmaceuticals | |
| BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast (NCT04091295) | Aveni Foundation | |
| An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG (NCT06443944) | CG Oncology, Inc. | |
| Intermediate Size Patient Population Expanded Access Protocol to Evaluate HB-adMSCs for the Treatment of Patients With Traumatic or Nontraumatic Brain Injury (NCT07164482) | Hope Biosciences Research Foundation | |
| Expanded Access to Telisotuzumab Adizutecan (NCT05982873) | AbbVie | |
| Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangitis (PBC) (NCT05448170) | GlaxoSmithKline | |
| Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Previously Treated With Linvoseltamab (NCT06631677) | Regeneron Pharmaceuticals | |
| Glioblastoma and Individualized Therapies (NCT05356312) | Zentrum fur Humangenetik Tuebingen | |
| 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol (NCT01370330) | Kieuhoa Vo | |
| Expanded Access to Triheptanoin (NCT03773770) | Ultragenyx Pharmaceutical Inc | |
| Early Access Program With Arimoclomol in US Patients With NPC (NCT04316637) | ZevraDenmark | |
| Expanded Access Program for Treatment With Ecopipam for Tourette's Disorder (NCT07093541) | Emalex Biosciences Inc. | |
| MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer (NCT06980506) | Monopar Therapeutics | |
| Expanded Access for Mezigdomide (NCT06994117) | Bristol-Myers Squibb | |
| Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS (NCT07614048) | Providence Health & Services | |
| Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel (NCT05776134) | Kite, A Gilead Company | |
| Managed Access Programs for BYL719, Alpelisib (NCT04085653) | Novartis Pharmaceuticals | |
| An Intermediate Expanded Use Trial of DFMO (NCT03581240) | Giselle Sholler | |
| CELZ-201-DDT for the Treatment of Chronic Lower Back Pain (NCT07137559) | Creative Medical Technology Holdings Inc | |
| Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis (NCT06915766) | Cogent Biosciences, Inc. | |
| Chronic Effect of Mat Pilates on Neuromotor, Cardiovascular Functions and Inflammatory Markers in Individuals Post-Stroke Stroke and High Blood Pressure (NCT06241339) | Rio de Janeiro State University | |
| A Compassionate Use Program to Provide Access to Sodium Thiosulfate (NCT04132882) | TRPHARM | |
| Danicopan Early Access Program (NCT05982938) | Alexion Pharmaceuticals, Inc. | |
| Pilot Study Using a Heat Pack to Treat Cutaneous Leishmaniasis (NCT01277796) | Universidad Peruana Cayetano Heredia | |
| Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302 (NCT07762638) | Idorsia Pharmaceuticals Ltd. | |
| NTX-001 to Repair Peripheral Nerve Transection(s) (NCT05565846) | Neuraptive Therapeutics Inc. | |
| Expanded Access Treatment Protocol With DCA for Patients With PDCD (NCT06931262) | Saol Therapeutics Inc | |
| Clinical Research on the Efficacy of Acupuncture Treatment in Chronic Low Back Pain (NCT00815529) | Kyunghee University Medical Center | |
| Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer (NCT07643831) | Genentech, Inc. | |
| Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors (NCT06948955) | Cogent Biosciences, Inc. | |
| Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy (NCT03863119) | Santhera Pharmaceuticals | |
| Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer (NCT06836648) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Managed Access Programs for LNP023, Iptacopan (NCT05222412) | Novartis Pharmaceuticals | |
| Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects with Treatment Resistant Herpes Simplex Virus Type 1 or 2 (NCT05844436) | AiCuris Anti-infective Cures AG | |
| Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy (NCT02494687) | Eastern Regional Medical Center | |
| Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy (NCT06956547) | ImmunityBio, Inc. | |
| Managed Access Programs for EXV811, Atrasentan (NCT07319585) | Novartis Pharmaceuticals | |